Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Jul 15;89(14):6319–6323. doi: 10.1073/pnas.89.14.6319

Androgen receptor gene mutations in human prostate cancer.

J R Newmark 1, D O Hardy 1, D C Tonb 1, B S Carter 1, J I Epstein 1, W B Isaacs 1, T R Brown 1, E R Barrack 1
PMCID: PMC49492  PMID: 1631125

Abstract

We screened human prostate cancer tissues for the presence of somatic mutations in the hormone binding domain of the androgen receptor (AR) gene. Exons E-H were amplified from genomic DNA using the polymerase chain reaction and analyzed by denaturing gradient gel electrophoresis (DGGE), which separates DNA fragments that differ by only a single base. We detected a mutation in exon E of the hormone binding domain in 1 of 26 specimens of untreated organ-confined stage B prostate cancer. The mutation was not detectable in peripheral blood lymphocyte DNA. Lymphocyte DNA (wild-type AR) migrated in DGGE as a single band. The tumor DNA migrated in DGGE as four bands, consistent with the presence of cells with mutant AR plus cells with wild-type AR and indicating that the tumor contained a somatic mutation. To our knowledge, a somatic AR gene mutation has not been reported previously. Sequencing revealed a G----A substitution in codon 730, changing valine to methionine. Codon 730 is in a region highly conserved among all steroid receptors. The abundance of the mutated fragment (about 50% of the DNA in the specimen) indicates its presence in cells with a growth advantage. A somatic mutation could be detected by DGGE if it represented at least 10% of the sample. Failure to detect mutations in other specimens analyzed may be due to this limit of sensitivity, the presence of mutations in other parts of the AR, or a low frequency of mutations in early stage disease.

Full text

PDF
6319

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. F., Lefkowitz R. J., Caron M. G., Cotecchia S. G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11354–11358. doi: 10.1073/pnas.88.24.11354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barrack E. R., Tindall D. J. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res. 1987;239:155–187. [PubMed] [Google Scholar]
  3. Bos J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed] [Google Scholar]
  4. Brown T. R., Lubahn D. B., Wilson E. M., French F. S., Migeon C. J., Corden J. L. Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity. Mol Endocrinol. 1990 Dec;4(12):1759–1772. doi: 10.1210/mend-4-12-1759. [DOI] [PubMed] [Google Scholar]
  5. Brown T. R., Lubahn D. B., Wilson E. M., Joseph D. R., French F. S., Migeon C. J. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8151–8155. doi: 10.1073/pnas.85.21.8151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Byravan S., Milhon J., Rabindran S. K., Olinger B., Garabedian M. J., Danielsen M., Stallcup M. R. Two point mutations in the hormone-binding domain of the mouse glucocorticoid receptor that dramatically reduce its function. Mol Endocrinol. 1991 Jun;5(6):752–758. doi: 10.1210/mend-5-6-752. [DOI] [PubMed] [Google Scholar]
  7. Carter B. S., Ewing C. M., Ward W. S., Treiger B. F., Aalders T. W., Schalken J. A., Epstein J. I., Isaacs W. B. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8751–8755. doi: 10.1073/pnas.87.22.8751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chakraborti P. K., Garabedian M. J., Yamamoto K. R., Simons S. S., Jr Creation of "super" glucocorticoid receptors by point mutations in the steroid binding domain. J Biol Chem. 1991 Nov 25;266(33):22075–22078. [PubMed] [Google Scholar]
  9. Chang C. S., Kokontis J., Liao S. T. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7211–7215. doi: 10.1073/pnas.85.19.7211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Charest N. J., Zhou Z. X., Lubahn D. B., Olsen K. L., Wilson E. M., French F. S. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol. 1991 Apr;5(4):573–581. doi: 10.1210/mend-5-4-573. [DOI] [PubMed] [Google Scholar]
  11. Chiarodo A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res. 1991 May 1;51(9):2498–2505. [PubMed] [Google Scholar]
  12. Coffey D. S., Isaacs J. T. Prostate tumor biology and cell kinetics--theory. Urology. 1981 Mar;17(Suppl 3):40–53. [PubMed] [Google Scholar]
  13. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Henderson B. E., Ross R. K., Pike M. C. Toward the primary prevention of cancer. Science. 1991 Nov 22;254(5035):1131–1138. doi: 10.1126/science.1957166. [DOI] [PubMed] [Google Scholar]
  15. Horoszewicz J. S., Leong S. S., Chu T. M., Wajsman Z. L., Friedman M., Papsidero L., Kim U., Chai L. S., Kakati S., Arya S. K. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980;37:115–132. [PubMed] [Google Scholar]
  16. Housley P. R., Sanchez E. R., Danielsen M., Ringold G. M., Pratt W. B. Evidence that the conserved region in the steroid binding domain of the glucocorticoid receptor is required for both optimal binding of hsp90 and protection from proteolytic cleavage. A two-site model for hsp90 binding to the steroid binding domain. J Biol Chem. 1990 Aug 5;265(22):12778–12781. [PubMed] [Google Scholar]
  17. Isaacs J. T. Development and characteristics of the available animal model systems for the study of prostatic cancer. Prog Clin Biol Res. 1987;239:513–576. [PubMed] [Google Scholar]
  18. Jenster G., van der Korput H. A., van Vroonhoven C., van der Kwast T. H., Trapman J., Brinkmann A. O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol. 1991 Oct;5(10):1396–1404. doi: 10.1210/mend-5-10-1396. [DOI] [PubMed] [Google Scholar]
  19. Kakizuka A., Miller W. H., Jr, Umesono K., Warrell R. P., Jr, Frankel S. R., Murty V. V., Dmitrovsky E., Evans R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663–674. doi: 10.1016/0092-8674(91)90112-c. [DOI] [PubMed] [Google Scholar]
  20. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., Fischbeck K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991 Jul 4;352(6330):77–79. doi: 10.1038/352077a0. [DOI] [PubMed] [Google Scholar]
  21. Lubahn D. B., Brown T. R., Simental J. A., Higgs H. N., Migeon C. J., Wilson E. M., French F. S. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9534–9538. doi: 10.1073/pnas.86.23.9534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lubahn D. B., Joseph D. R., Sar M., Tan J., Higgs H. N., Larson R. E., French F. S., Wilson E. M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol. 1988 Dec;2(12):1265–1275. doi: 10.1210/mend-2-12-1265. [DOI] [PubMed] [Google Scholar]
  23. Lyons J., Landis C. A., Harsh G., Vallar L., Grünewald K., Feichtinger H., Duh Q. Y., Clark O. H., Kawasaki E., Bourne H. R. Two G protein oncogenes in human endocrine tumors. Science. 1990 Aug 10;249(4969):655–659. doi: 10.1126/science.2116665. [DOI] [PubMed] [Google Scholar]
  24. McGuire W. L., Chamness G. C., Fuqua S. A. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov;5(11):1571–1577. doi: 10.1210/mend-5-11-1571. [DOI] [PubMed] [Google Scholar]
  25. Power R. F., Mani S. K., Codina J., Conneely O. M., O'Malley B. W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991 Dec 13;254(5038):1636–1639. doi: 10.1126/science.1749936. [DOI] [PubMed] [Google Scholar]
  26. Ris-Stalpers C., Trifiro M. A., Kuiper G. G., Jenster G., Romalo G., Sai T., van Rooij H. C., Kaufman M., Rosenfield R. L., Liao S. Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics. Mol Endocrinol. 1991 Oct;5(10):1562–1569. doi: 10.1210/mend-5-10-1562. [DOI] [PubMed] [Google Scholar]
  27. Rundlett S. E., Wu X. P., Miesfeld R. L. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol. 1990 May;4(5):708–714. doi: 10.1210/mend-4-5-708. [DOI] [PubMed] [Google Scholar]
  28. Sadi M. V., Walsh P. C., Barrack E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991 Jun 15;67(12):3057–3064. doi: 10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  29. Sharif M., Privalsky M. L. v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action. Cell. 1991 Sep 6;66(5):885–893. doi: 10.1016/0092-8674(91)90435-2. [DOI] [PubMed] [Google Scholar]
  30. Sheffield V. C., Cox D. R., Lerman L. S., Myers R. M. Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci U S A. 1989 Jan;86(1):232–236. doi: 10.1073/pnas.86.1.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Simental J. A., Sar M., Lane M. V., French F. S., Wilson E. M. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991 Jan 5;266(1):510–518. [PubMed] [Google Scholar]
  32. Sone T., Marx S. J., Liberman U. A., Pike J. W. A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. Mol Endocrinol. 1990 Apr;4(4):623–631. doi: 10.1210/mend-4-4-623. [DOI] [PubMed] [Google Scholar]
  33. Traystman M. D., Higuchi M., Kasper C. K., Antonarakis S. E., Kazazian H. H., Jr Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene. Genomics. 1990 Feb;6(2):293–301. doi: 10.1016/0888-7543(90)90569-g. [DOI] [PubMed] [Google Scholar]
  34. Usala S. J., Menke J. B., Watson T. L., Wondisford F. E., Weintraub B. D., Bérard J., Bradley W. E., Ono S., Mueller O. T., Bercu B. B. A homozygous deletion in the c-erbA beta thyroid hormone receptor gene in a patient with generalized thyroid hormone resistance: isolation and characterization of the mutant receptor. Mol Endocrinol. 1991 Mar;5(3):327–335. doi: 10.1210/mend-5-3-327. [DOI] [PubMed] [Google Scholar]
  35. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  36. Wilson J. D. Syndromes of androgen resistance. Biol Reprod. 1992 Feb;46(2):168–173. doi: 10.1095/biolreprod46.2.168. [DOI] [PubMed] [Google Scholar]
  37. van der Kwast T. H., Schalken J., Ruizeveld de Winter J. A., van Vroonhoven C. C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 1991 May 10;48(2):189–193. doi: 10.1002/ijc.2910480206. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES